Benefits and risks of the treatment with fibrates––a comprehensive summary
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Benefits and risks of the treatment with fibrates––a comprehensive summary
Authors
Keywords
-
Journal
Expert Review of Clinical Pharmacology
Volume 11, Issue 11, Pages 1099-1112
Publisher
Informa UK Limited
Online
2018-10-17
DOI
10.1080/17512433.2018.1537780
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The effects of folate supplementation on glucose metabolism and risk of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
- (2018) Jie V. Zhao et al. ANNALS OF EPIDEMIOLOGY
- Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial
- (2018) Eiichi Araki et al. DIABETES CARE
- Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan
- (2018) Masanari Kuwabara et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- PPAR Agonists and Metabolic Syndrome: An Established Role?
- (2018) Margherita Botta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial
- (2018) Hidenori Arai et al. Journal of Atherosclerosis and Thrombosis
- Increased Cardiovascular Risk in Hypertriglyceridemic Patients with Statin-Controlled LDL Cholesterol
- (2018) Gregory A Nichols et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
- (2018) Christophe Corpechot et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of fibrates on glycemic parameters: A systematic review and meta-analysis of randomized placebo-controlled trials
- (2018) Luis E. Simental-Mendía et al. PHARMACOLOGICAL RESEARCH
- Health-related quality of life in gout in primary care: Baseline findings from a cohort study
- (2018) Priyanka Chandratre et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance
- (2018) Ikuro Matsuba et al. Journal of Diabetes Investigation
- Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome
- (2018) Rabia Chaudhry et al. Expert Review of Clinical Pharmacology
- Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study
- (2018) Boris Waldman et al. Lancet Diabetes & Endocrinology
- Comparison of fenofibrate and pioglitazone effects on patients with nonalcoholic fatty liver disease
- (2017) Malek Yaghoubi et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- The peroxisome proliferator-activated receptor pan-agonist bezafibrate suppresses microvascular inflammatory responses of retinal endothelial cells and vascular endothelial growth factor production in retinal pigmented epithelial cells
- (2017) Ayumi Usui-Ouchi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Efficacy and Safety of Long-term Coadministration of Fenofibrate and Ezetimibe in Patients with Combined Hyperlipidemia: Results of the EFECTL Study
- (2017) Shinichi Oikawa et al. Journal of Atherosclerosis and Thrombosis
- Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase
- (2017) Ajay Gupta et al. LANCET
- The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement
- (2017) Vasilios G. Athyros et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Effects of peroxisome proliferator activated receptors (PPAR)-γ and -α agonists on cochlear protection from oxidative stress
- (2017) Marijana Sekulic-Jablanovic et al. PLoS One
- Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study
- (2016) Sze Ling Chan et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Severe hypoglycemia in users of sulfonylurea antidiabetic agents and antihyperlipidemics
- (2016) CE Leonard et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- A Systematic Review and Meta-Analysis of Controlled Trials on the Effects of Statin and Fibrate Therapies on Plasma Homocysteine Levels
- (2016) Amirhossein Sahebkar et al. CURRENT MEDICINAL CHEMISTRY
- Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin
- (2016) Paul M Ridker EUROPEAN HEART JOURNAL
- 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
- (2016) Alberico L. Catapano et al. EUROPEAN HEART JOURNAL
- Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
- (2016) Roberto Ferrari et al. EUROPEAN HEART JOURNAL SUPPLEMENTS
- Lipid-lowering agents inhibit hepatic steatosis in a non-alcoholic steatohepatitis-derived hepatocellular carcinoma mouse model
- (2016) Kazuki Orime et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters
- (2016) Aleksi Tornio et al. Expert Opinion on Drug Metabolism & Toxicology
- Efficacy and safety of fenofibrate as an add-on in patients with elevated triglyceride despite receiving statin treatment
- (2016) Shuiping Zhao et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Fenofibrate reduces cisplatin-induced apoptosis of renal proximal tubular cells via inhibition of JNK and p38 pathways
- (2016) Penjai Thongnuanjan et al. JOURNAL OF TOXICOLOGICAL SCIENCES
- Non-alcoholic fatty liver disease and dyslipidemia: An update
- (2016) Niki Katsiki et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Current and future trends in the lipid lowering therapy
- (2016) Bogusław Okopień et al. Pharmacological Reports
- Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis
- (2016) Amirhossein Sahebkar et al. PHARMACOLOGICAL RESEARCH
- Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia
- (2015) Amit V. Khera et al. AMERICAN JOURNAL OF CARDIOLOGY
- Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients
- (2015) Luís Masana et al. ATHEROSCLEROSIS
- Impact of fibrate therapy on plasma plasminogen activator inhibitor-1: A systematic review and meta-analysis of randomized controlled trials
- (2015) Amirhossein Sahebkar et al. ATHEROSCLEROSIS
- Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes
- (2015) Takahisa Hirose et al. Journal of Atherosclerosis and Thrombosis
- Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials
- (2015) Giuseppe Derosa et al. PHARMACOLOGICAL RESEARCH
- Long-term risk of cardiovascular events across a spectrum of adverse major plasma lipid combinations in the Framingham Heart Study
- (2014) Charlotte Andersson et al. AMERICAN HEART JOURNAL
- Gemfibrozil disrupts lysophosphatidylcholine and bile acid homeostasis via PPARα and its relevance to hepatotoxicity
- (2014) Aiming Liu et al. ARCHIVES OF TOXICOLOGY
- Residual macrovascular risk in 2013: what have we learned?
- (2014) Jean-Charles Fruchart et al. Cardiovascular Diabetology
- Ideal Cardiovascular Health
- (2014) Vanessa Xanthakis et al. CIRCULATION
- The Effects of Medical Management on the Progression of Diabetic Retinopathy in Persons with Type 2 Diabetes
- (2014) Emily Y. Chew et al. OPHTHALMOLOGY
- Rhabdomyolysis as a Clinical Manifestation of Association With Ciprofibrate, Sirolimus, Cyclosporine, and Pegylated Interferon-α in Liver-Transplanted Patients: A Case Report and Literature Review
- (2014) A.G. dos Santos et al. TRANSPLANTATION PROCEEDINGS
- Effect of fibrate treatment on liver function tests in patients with the metabolic syndrome
- (2014) Nirav Gandhi et al. SpringerPlus
- Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study
- (2013) Tamio Teramoto et al. Cardiovascular Diabetology
- The Role of Fibrate Treatment in Dyslipidemia: An Overview
- (2013) Niki Katsiki et al. CURRENT PHARMACEUTICAL DESIGN
- A case of rhabdomyolysis complicated with acute renal failure after resumption of fenofibrate therapy: A first report
- (2013) Muharrem Kiskac et al. INDIAN JOURNAL OF PHARMACOLOGY
- Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: A clinical update
- (2013) Ž. Reiner NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Validating the 5Fs mnemonic for cholelithiasis: time to include family history
- (2013) Gary Bass et al. POSTGRADUATE MEDICAL JOURNAL
- Gout as a risk factor for myocardial infarction and stroke in England: evidence from record linkage studies
- (2013) Olena O. Seminog et al. RHEUMATOLOGY
- Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction
- (2012) Alexander Tenenbaum et al. Cardiovascular Diabetology
- Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?
- (2012) Alexander Tenenbaum et al. Cardiovascular Diabetology
- Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study
- (2012) Tamio Teramoto et al. Cardiovascular Diabetology
- Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study
- (2012) Markus Herrmann et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience
- (2012) D. E. Bonds et al. DIABETOLOGIA
- Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose
- (2012) Lukasz Buldak et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Lipid-Modifying Therapies and Risk of Pancreatitis
- (2012) David Preiss et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Metabolomics reveals an essential role for peroxisome proliferator-activated receptor α in bile acid homeostasis
- (2012) Fei Li et al. JOURNAL OF LIPID RESEARCH
- Effects of Fibrates in Kidney Disease
- (2012) Min Jun et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Gout and the risk for incident heart failure and systolic dysfunction
- (2012) Eswar Krishnan BMJ Open
- Association Between Gout and All-Cause as well as Cardiovascular Mortality: A Systematic Review
- (2012) Kathrin Lottmann et al. Current Rheumatology Reports
- Fenofibrate Reduces C-Reactive Protein Levels in Hypertriglyceridemic Patients With High Risks for Cardiovascular Diseases
- (2012) Yun Joo Min et al. Korean Circulation Journal
- Incidence of Hospitalized Rhabdomyolysis with Statin and Fibrate Use in an Insured US Population
- (2011) Kandace L Amend et al. ANNALS OF PHARMACOTHERAPY
- Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study
- (2011) Tohru Noguchi et al. ATHEROSCLEROSIS
- Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis
- (2011) Meng Lee et al. ATHEROSCLEROSIS
- Excess of Rare Variants in Non–Genome-Wide Association Study Candidate Genes in Patients With Hypertriglyceridemia
- (2011) Christopher T. Johansen et al. Circulation-Cardiovascular Genetics
- Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: A rare case report
- (2011) Fatih Mehmet Erdur et al. CLINICAL BIOCHEMISTRY
- Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges
- (2011) Uchechukwu K. Sampson et al. Current Atherosclerosis Reports
- “European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL Subclasses
- (2011) Dimitri P. Mikhailidis et al. Current Vascular Pharmacology
- Assessment and Clinical Relevance of Non-Fasting and Postprandial Triglycerides: An Expert Panel Statement
- (2011) Genovefa D. Kolovou et al. Current Vascular Pharmacology
- Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study
- (2011) Supna Sandhu et al. Lipids in Health and Disease
- Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid
- (2010) C. Levy et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study
- (2010) T. M. E. Davis et al. DIABETOLOGIA
- Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
- (2010) Min Jun et al. LANCET
- Effects of Medical Therapies on Retinopathy Progression in Type 2 Diabetes
- (2010) NEW ENGLAND JOURNAL OF MEDICINE
- Antiplatelet Actions of Statins and Fibrates Are Mediated by PPARs
- (2009) Ferhana Y. Ali et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Severe hypertriglyceridemia and pancreatitis: presentation and management
- (2009) Nils Ewald et al. CURRENT OPINION IN LIPIDOLOGY
- Pleiotropic Action of Short-Term Metformin and Fenofibrate Treatment, Combined With Lifestyle Intervention, in Type 2 Diabetic Patients With Mixed Dyslipidemia
- (2009) M. Pruski et al. DIABETES CARE
- After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study: Implications for Fenofibrate
- (2008) Frank M. Sacks AMERICAN JOURNAL OF CARDIOLOGY
- Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: A role for combination fibrate therapy
- (2008) Sergio Fazio CLINICAL THERAPEUTICS
- The syndrome of rhabdomyolysis: Complications and treatment
- (2008) Yiannis S. Chatzizisis et al. European Journal of Internal Medicine
- Characterization and properties of preβ-HDL particles formed by ABCA1-mediated cellular lipid efflux to apoA-I
- (2008) Phu T. Duong et al. JOURNAL OF LIPID RESEARCH
- Myotoxicity of gemfibrozil in Cynomolgus monkey model and its relationship to pharmacokinetic properties
- (2008) Aiming Liu et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now